This report analyses the financial performance of CVS Health for the 2019. You will find all the necessary details regarding company's profitability, volume growth, indebtedness and a comparison with selected peers.
CVS Health announced a net profit of USD 6,634 mil in 2019, up 1% when compared to the last year. Sales increased 32% yoy to USD 256,776 mil, EBITDA rose 182% to USD 19,028 mil and net margin amounted to 2.58%. CVS Health stock appreciated 17.3% in 2019 to USD 72.6 per share and the stock traded at 12-month trailing PE of 14.3 and EV/EBITDA of 9.34x at the end of 2019.
The key highlights are:
Sales increased 32.0% yoy to USD 256,776 mil in 2019. That’s compared to average growth of 13.1% in the last three years and 10.1% when compared to the average annual increase in the last decade.
EBITDA amounted to USD 19,028 mil and grew 182% when compared to last year. EBITDA margin reached 7.41%, up 0.977 pp when compared to 5-year average.
Company’s indebtedness rose when measured by Net Debt/Equity and reached 126% at the end of the year. When compared to EBITDA, net debt fell to 4.25x.
CVS Health netted USD 6,634 mil to its shareholders in the last year, up 42.9% when compared to the average seen in the last five years. The company produced a return on capital of 3.65% and return on equity of 10.8% in the last year.
CVS Health stock traded at USD 72.6 per share at the end of 2019 implying a market capitalization of USD 96,726 mil and enterprise value of USD 177,672 mil. This puts the stock at the 12-month trailing price to earnings of 14.3x and EV/EBITDA of 9.34x as of the end of 2019. Over the last five years, the stock price has decreased by 2.78% a year on average and the firm generated its shareholders an average return on equity of 11.1%.
Helgi Library 
